Compare BioNTech SE - ADR (BNTX) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.75. The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | EMB | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Fixed Income |
52-Week High | $119.34 | $97.74 |
52-Week Low | $83.89 | $91.52 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
EMB trades at $95.38, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The stock shows oversold conditions with a 6-day RSI at 29.09, while recent corporate actions include scheduled dividends for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on similar ETFs.
The outlook remains cautious due to technical weakness and macro risks in emerging markets. Investment opportunity lies in potential oversold rebound, but risks include sovereign default exposure and interest rate sensitivity. Investor sentiment is mixed amid global fixed income volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
